Novavax, Inc., a biotechnology company that develops next-generation vaccines for serious infectious diseases, announced that it has closed an advance purchase agreement ( APA) with Gavi, the Vaccine Alliance (Gavi) for the supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to produce and distribute 350…